CA2707488C - Triazolo[4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms - Google Patents

Triazolo[4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms Download PDF

Info

Publication number
CA2707488C
CA2707488C CA2707488A CA2707488A CA2707488C CA 2707488 C CA2707488 C CA 2707488C CA 2707488 A CA2707488 A CA 2707488A CA 2707488 A CA2707488 A CA 2707488A CA 2707488 C CA2707488 C CA 2707488C
Authority
CA
Canada
Prior art keywords
compound
treatment
thrombus
day
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2707488A
Other languages
English (en)
French (fr)
Other versions
CA2707488A1 (en
Inventor
Jean-Baptiste Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA2707488A1 publication Critical patent/CA2707488A1/en
Application granted granted Critical
Publication of CA2707488C publication Critical patent/CA2707488C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2707488A 2007-12-03 2008-12-02 Triazolo[4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms Expired - Fee Related CA2707488C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301616.4 2007-12-03
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (2)

Publication Number Publication Date
CA2707488A1 CA2707488A1 (en) 2009-06-11
CA2707488C true CA2707488C (en) 2015-07-28

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2707488A Expired - Fee Related CA2707488C (en) 2007-12-03 2008-12-02 Triazolo[4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms

Country Status (24)

Country Link
US (2) US20100298350A1 (enExample)
EP (1) EP2229172B1 (enExample)
JP (1) JP5701060B2 (enExample)
KR (1) KR101563757B1 (enExample)
CN (2) CN101883565A (enExample)
AU (1) AU2008331984B2 (enExample)
BR (1) BRPI0819458A2 (enExample)
CA (1) CA2707488C (enExample)
CY (1) CY1115760T1 (enExample)
DK (1) DK2229172T3 (enExample)
EA (1) EA201000928A1 (enExample)
ES (1) ES2522317T3 (enExample)
HR (1) HRP20141081T1 (enExample)
IL (1) IL205613A (enExample)
MX (1) MX2010006101A (enExample)
MY (1) MY159656A (enExample)
NZ (1) NZ585513A (enExample)
PL (1) PL2229172T3 (enExample)
PT (1) PT2229172E (enExample)
RS (1) RS53635B1 (enExample)
SI (1) SI2229172T1 (enExample)
UA (1) UA100864C2 (enExample)
WO (1) WO2009072967A1 (enExample)
ZA (1) ZA201003599B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Also Published As

Publication number Publication date
IL205613A0 (en) 2010-11-30
ES2522317T3 (es) 2014-11-14
PT2229172E (pt) 2014-11-03
SI2229172T1 (sl) 2014-12-31
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
UA100864C2 (uk) 2013-02-11
HK1148195A1 (en) 2011-09-02
KR101563757B1 (ko) 2015-10-27
CA2707488A1 (en) 2009-06-11
ZA201003599B (en) 2012-10-31
NZ585513A (en) 2012-07-27
AU2008331984A1 (en) 2009-06-11
CN101883565A (zh) 2010-11-10
MX2010006101A (es) 2010-10-04
BRPI0819458A2 (pt) 2015-05-05
KR20100099175A (ko) 2010-09-10
HRP20141081T1 (hr) 2015-01-02
JP5701060B2 (ja) 2015-04-15
CY1115760T1 (el) 2017-01-25
PL2229172T3 (pl) 2015-01-30
DK2229172T3 (da) 2014-11-10
US20150272955A1 (en) 2015-10-01
EP2229172A4 (en) 2012-12-26
AU2008331984B2 (en) 2012-08-16
EP2229172A1 (en) 2010-09-22
CN103919781A (zh) 2014-07-16
MY159656A (en) 2017-01-13
RS53635B1 (sr) 2015-04-30
IL205613A (en) 2015-04-30
EA201000928A1 (ru) 2010-12-30
JP2011505417A (ja) 2011-02-24
US20100298350A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US11478440B2 (en) Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
JP5819328B2 (ja) ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
CA2681597A1 (en) Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
AU2008331984B2 (en) Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms
US20120046333A1 (en) Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis
Acun et al. The effect of single-dose intraperitoneal bevacizumab on peritoneal adhesion formation
CN121263189A (zh) 用于去除和抑制衰老细胞的组合物及其用途
WO2010031859A1 (en) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
MXPA06013157A (es) Uso de dipiridamol para el tratamiento de la resistencia a los inhibidores de plaquetas.
TW202045180A (zh) 治療纖維化之方法
WO2020092117A2 (en) Killing senescent cells and treating senescence-associated diseases or disorders using a combination of a bcl inhibitor and an mcl-1 inhibitor
HK1148195B (en) Ticagrelor for treatment of abdominal aortic aneurysms
JP2018537522A (ja) 組合せ
WO2022043381A1 (en) Anti-fibrotic combination
KR101736832B1 (ko) 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물
Ucar et al. The effects of interferon α2b on chemically-induced peritoneal fibrosis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats
HK1224599A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
HK1224599A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131127

MKLA Lapsed

Effective date: 20201202